He turned $10,000 and a stubborn refusal to accept "no treatment available" into one of the largest psychedelic drug programs on Earth.
Sam Clark // The chemist-in-chief of the human brain
Sam Clark runs a biotech company that licenses drugs the giants gave up on, then rebuilds their chemistry until they work. That is the strange, specific thing to know first. Terran Biosciences, which he founded in 2017, has bought shelved and stalled molecules from Sanofi and Pierre Fabre, and it employs more than forty chemists whose entire job is to make old compounds behave in new ways. Oral versions of DMT. Long-acting MDMA. Novel salts of psilocybin. The lab is a workshop for reworking the pharmacology of the mind.
Clark started it with $10,000. He was in medical school, living in a dorm, when he wired the seed money and began licensing his first assets. Most founders would call that a story about scrappiness. Clark tells it as a story about conviction. He had watched close family members live with severe mental illness and dementia, and somewhere between the neuroscience labs at MIT and the clinical wards at Columbia he decided the field's answers were not good enough. So he left the conventional track - MD, PhD, the whole apparatus - to invent instead.
The Heraclitus quote is not decoration. It is close to an operating manual. Clark treats the brain, the science, and the company as things in permanent motion, which is a convenient philosophy for a founder whose whole method depends on returning to compounds the rest of the industry considers finished. Nothing is fixed. Not the molecule, not the market, not the man holding the patent.
When Clark leaned into schizophrenia, neuropsychiatry was deeply unfashionable in pharma. Big companies had retreated. The trials were hard, the biology messy, the payoffs uncertain. He went in anyway. That is the tell of how he thinks: crowded fields are expensive and thin margins; abandoned fields are where the overlooked value sits. His pipeline reads like a list of second chances - eplivanserin and volinanserin from Sanofi, idazoxan from Pierre Fabre, each one a drug with a history and unfinished business.
He is careful, though, not to oversell the psychedelics that made his company famous. Clark's framing is unusually sober for the space. The compounds, in his telling, are not a cure. They are a mechanism - rapid-acting, longer-lasting than what came before, with real advantages in safety and time to onset. That is enough. He would rather be precise than evangelical.
Clark is the named inventor on more than 200 patent applications. He is the sole inventor on the first-ever granted patents for new forms of psilocybin and MDMA - not new uses, new forms, the molecules themselves. It is the kind of statistic that sounds like a rounding error until you sit with it. One person, one signature, an entire frontier of neuropsychiatric chemistry filed under his name.
Terran is not only a chemistry shop. Its drug design engine is paired with an AI-enabled imaging platform. NM-101, the company's cloud software for reading neuromelanin MRI scans, has been described as the world's first FDA-cleared tool of its kind. The pattern holds across everything Clark builds: find the thing nobody has done yet, then do it first and patent the result.
The company Clark built is deliberately flat. A small central team, a roster of subject-matter experts brought in as consultants, and a chemistry bench that punches far above the payroll. He runs it lean because he has to - the whole thesis is doing more with less than the industry spends - and because he seems to genuinely prefer it. "The best folks are hard to find," he has said, "but once you do find them, hold on to them." For a man with 200 patents, the scarcest resource turns out to be people, not ideas.
Ask him about the plan and you get a founder who does not much believe in backup plans. Clark describes his approach as all or nothing. No fallback, no hedge, just relentless effort pointed at a single outcome. It is a risky way to build anything. It is also, for now, working - Terran has cleared clinical milestones, signed pharma partnerships, and kept its costs below the norm while doing it.
What he wants, in the end, is bigger than any one drug. Clark talks about destigmatizing neurological and psychiatric disease, about inspiring the rest of the industry to take another look at the patients everyone else has written off. The river keeps moving. He intends to keep stepping in.